| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5581782 | Clinical Lymphoma Myeloma and Leukemia | 2017 | 9 Pages |
Abstract
IFRT used before or after ASCT might partially compensate for worse prognostic factors among the overall population; subgroup analysis showed a trend for survival benefit at 3 years in patients with limited stage disease at relapse and PET+ before ASCT.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Mario Levis, Cristina Piva, Andrea Riccardo Filippi, Barbara Botto, Paolo Gavarotti, Patrizia Pregno, Maura Nicolosi, Roberto Freilone, Guido Parvis, Daniela Gottardi, Umberto Vitolo, Umberto Ricardi,